

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 004</b>
---	-----------------------------------	---

**Accreditation No: LAB 004**

**Awarded to**

Quality Control Laboratory  
**Platinum Pharmaceutical (Pvt.) Limited**  
A-20, North Western Industrial Zone, Bin Qasim  
Karachi-Pakistan

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **03-06-2004** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **02-06-2027**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

**26-09-2024**

Date

SD

Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 004</b>
---	-----------------------------------	---

**Testing Laboratory.**

**Accreditation Scope of Quality Control Laboratory, Platinum Pharmaceutical (Pvt.) Limited, A-20, North Western Industrial Zone, Bin Qasim, Karachi-Pakistan.**

**Permanent laboratory premises**

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Brethin Tablets 2.5 mg	Chemical	Assay	USP 2024 monograph ;<621>
		Dissolution	USP 2024 monograph ;<711>
Cabok Tablets 5 mg and 10 mg	Chemical	Assay	BP2024- Monograph: Vol-III- Page# 159-160
		Dissolution	BP 2024: Appendix XII B. BP2024-Monograph: Vol-III- Page#159-160
Cardaxen Tablets 25 mg, 50 mg 100 mg,	Chemical	Assay	BP2024 - Monograph: Vol-III Page#185-186
Cedrox Tablets 1 g	Chemical	Assay	USP 2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Cedrox capsules 500 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Cedrox Suspension (125 mg / 5 ml) and (250 mg / 5 ml)	Chemical	Assay	USP2024 monograph ;<621>
Ceftas Suspension (100 mg / 5 ml)	Chemical	Assay	USP2024 monograph ;<621>
	Chemical	Assay	USP2024 monograph ;<621>

**26-09-2024**

Date

sd

Director



## ACCREDITATION DOCUMENT

**F-06/02**  
**Issue Date: 18/08/2020**  
**Rev. No: 09**  
**LAB 004**

Dolonap Tablets 250 mg & 500 mg		Dissolution	USP2024 monograph ;<711>
Emiset Tablets 10 mg	Chemical	Assay	BP2024 - Monograph: Vol-III-Page#581-582
		Dissolution	BP 2024: Appendix XII B. BP2024-Monograph: Vol-III-Page #581-582
Fastaid Tablets 25 mg, 50 mg, and 75 mg	Chemical	Assay	BP2024 - Monograph: Vol-III-Page # 545-546
Nordox Capsules 100 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Novelink Capsules 500 mg	Chemical	Assay	USP2024 monograph ;<621>
Prodent Mouthwash	Chemical	Assay	Internal- QC/TM/DP/080
Reducid Tablets 20 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Reducid Tablets 40 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Seizunil Tablets 200 mg and 400 mg	Chemical	Assay	BP2024 - Monograph: Vol-III-Page # 303
Solvocef Capsules 500 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Suprox Tablets 250 mg and 500 mg	Chemical	Assay	USP2024 monograph ;<621>
		Dissolution	USP2024 monograph ;<711>
Synalgo Tablets 100 mg	Chemical	Assay	USP2024 monograph ;<621>
Velora Capsules 250 mg and 500 mg	Chemical	Assay	BP2024 - Monograph: Vol-III-Page # 325-327
		Dissolution	BP 2024: Appendix XII B. BP2024-Monograph: Vol-III-Page # 325-327
Velora Dry Suspension (125 mg / 5 ml) and (250 mg / 5 ml)	Chemical	Assay	BP2024 - Monograph: Vol-III Page # 329-331

**26-09-2024**

Date

sd

Director